What is InterCure?
InterCure, operating under the brand Canndoc, stands as the foremost cannabis enterprise beyond North America. Its subsidiary, Canndoc, is recognized as Israel's largest licensed producer of cannabis, distinguished by its pharmaceutical-grade, Good Manufacturing Practices (GMP) certified medical cannabis products. The company capitalizes on a robust, market-leading distribution network, strategic international alliances, and a high-margin, vertically integrated "seed-to-sale" operational model. This comprehensive approach solidifies InterCure's dominance in the Israeli market and provides a strong foundation for its global expansion initiatives.
How much funding has InterCure raised?
InterCure has raised a total of $11M across 1 funding round:
Share Placement
$11M
Share Placement (2020): $11M, investors not publicly disclosed
What's next for InterCure?
With a substantial enterprise-level funding context and a recent major strategic investment, InterCure is poised for accelerated global expansion. The company's established infrastructure, including its leading distribution channels and GMP-certified production capabilities, provides a solid platform for scaling its operations internationally. Future strategic moves are likely to focus on leveraging these assets to penetrate new markets and further solidify its position as a global leader in the medical cannabis sector. The company's ability to attract significant capital indicates strong investor confidence in its business model and future prospects.
See full InterCure company page
